RALEIGH, N.C., March 10, 2016 (GLOBE NEWSWIRE) — INC Research Holdings, Inc. (Nasdaq:INCR), a leading, global Phase I to IV contract research organization (CRO), today announced the appointment of Judith Ng-Cashin, MD, as Chief Scientific Officer. Dr. Ng-Cashin will lead the integration of the Company’s industry-recognized therapeutic and medical/scientific expertise for Phase I to IV clinical trials. She will be responsible for scientific, medical and ethical governance matters, including collaboration with key medical and scientific stakeholders to strengthen INC’s position as a collaborative partner to clinical practice, sponsor and academic organizations.
“INC has long been recognized as the therapeutically-focused CRO,” said Michael Gibertini, PhD, President, Clinical Development. “The appointment of Dr. Judith Ng-Cashin further demonstrates our commitment to providing our customers with high-quality clinical development services grounded in practical medical science and industry-leading therapeutic expertise. With more than 20 years of experience in drug discovery and development, clinical research, bench science and clinical medicine, Dr. Ng-Cashin has distinguished herself in the development of novel therapies. Her proven track record will be invaluable as we work to further connect our medical and therapeutic teams at INC in support of our customers’ clinical development goals.”
Dr. Ng-Cashin joins INC Research from another top-tier CRO where she served as Vice President, Medical Strategy, Office of the CMSO with responsibility for oversight of medical ethics and governance across the global business and most recently as Vice President, Advisory Services. Her experience also includes nine years with GlaxoSmithKline in senior medical leadership roles. Dr. Ng-Cashin’s expertise is wide-ranging, spanning all stages of clinical research and including targeted research in melanoma, HIV and other infectious diseases.
Dr. Ng-Cashin holds a Doctor of Medicine degree from Rush Medical College in Chicago. She completed her residency training at the University of Chicago Medical Center and her subspecialty fellowship training at the University of North Carolina at Chapel Hill.
About INC Research
INC Research (Nasdaq:INCR) is a leading global contract research organization (“CRO”) providing the full range of Phase I to Phase IV clinical development services for the biopharmaceutical and medical device industries. Leveraging the breadth of our service offerings and the depth of our therapeutic expertise across multiple patient populations, INC
Research connects customers, clinical research sites and patients to accelerate the delivery of new medicines to market. The Company was named “Best Contract Research Organization” in December 2015 by an independent panel for Scrip Intelligence, and ranked “Top CRO to Work With” among large global CROs in the 2015 CenterWatch Global Investigative Site Relationship Survey. INC Research is headquartered in Raleigh, NC, with operations across six continents and experience spanning more than 110 countries.
CONTACT: CONTACT: Investor Relations Contact: Ronnie Speight Vice President, Investor Relations Phone: +1 (919) 745-2745 Email: Investor.Relations@incresearch.com Press/Media Contact: Lori Dorer Senior Director, Corporate Communications Phone: +1 (513) 763-1380 Email: Corporate.Communications@incresearch.com
